MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.

6533b7d5fe1ef96bd1263d9c

RESEARCH PRODUCT

MR-imaging features of hepatocellular carcinoma capsule appearance in cirrhotic liver: comparison of gadoxetic acid and gadobenate dimeglumine.

Dario Picone Roberto Lagalla Massimo Midiri Giuseppe Brancatelli Giuseppe Cabibbo Marco Dioguardi Burgio

subject

Gadolinium DTPA Liver Cirrhosis Male Cirrhotic liver medicine.medical_specialty Gadoxetic acid Carcinoma Hepatocellular Hepatocellular carcinoma Urology Gadoxetic acid Contrast Media Sensitivity and Specificity 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Meglumine Internal medicine Gadobenate dimeglumine medicine Organometallic Compounds Humans Radiology Nuclear Medicine and imaging GADOBENATE DIMEGLUMINE Capsule Aged Retrospective Studies Aged 80 and over Radiological and Ultrasound Technology business.industry Liver Neoplasms Gastroenterology Capsule Reproducibility of Results Hepatology HCCS Middle Aged medicine.disease Image Enhancement Mr imaging Magnetic Resonance Imaging digestive system diseases Liver 030220 oncology & carcinogenesis Hepatocellular carcinoma Female Radiology business MR imaging medicine.drug

description

Purpose: The purpose of the study is to compare the MR-imaging features of hepatocellular carcinoma (HCC) capsule appearance on gadoxetic acid and gadobenate dimeglumine-enhanced MR imaging, using imaging-based presumptive diagnosis of HCC as the reference standard. Methods: Gadoxetic acid and gadobenate dimeglumine-enhanced MR imaging of 51 patients with 71 HCCs were retrospectively reviewed. Three readers graded in consensus, using a five-point scale, the presence (score 4–5) of capsule appearance on images obtained during T1-weighted GRE portal venous phase (PVP), 3-min phase, and hepatobiliary phase (HBP). The Fisher's exact test and the t student unpaired test were performed. Results: A hyperintense capsule appearance was present either on PVP or 3-min phase in 11/46 and in 24/25 HCCs imaged with gadoxetic acid and gadobenate dimeglumine-enhanced MR imaging, respectively (24% vs. 96% p < 0.001). A hypointense capsule appearance was present on HBP in 8/46 and 0/22 HCCs evaluated with gadoxetic acid and gadobenate dimeglumine-enhanced MR imaging, respectively (17% vs. 0% p = 0.046). A capsule appearance was detected either on PVP, 3-min phase, or HBP in 17/46 (37%) HCCs after gadoxetic acid injection and in 24/25 (96%) HCCs after gadobenate dimeglumine injection (p < 0.001). Conclusions: A capsule appearance was more frequently seen on gadobenate dimeglumine-enhanced MR imaging when compared to gadoxetic acid-enhanced MR imaging.

year	journal	country	edition	language
2016-04-06	Abdominal radiology (New York)

10.1007/s00261-016-0726-7 https://pubmed.ncbi.nlm.nih.gov/27052455